How Often Should Kidney Function Be Checked?

Interpreting Year-Over-Year Trends: A Practical Patient Guide

Knowing your monitoring schedule is only part of the equation. Understanding what your results mean — and when they are trending in the wrong direction — gives you the information you need to advocate for timely care.

What “stable” looks like. A stable patient is one whose eGFR varies by less than 5 mL/min per year (within the expected measurement variability of the test), whose ACR stays within the same KDIGO category from year to year, whose blood pressure stays below the target of 130/80 mmHg, and whose electrolytes remain within normal range. Stable results on two consecutive monitoring visits are genuinely reassuring — they indicate that the disease is not progressing at a pace that needs to change the treatment plan.

What slow progression looks like. A decline in eGFR of 2 to 4 mL/min per year, with the ACR remaining stable or changing by less than one full category, represents the slower end of CKD progression. This pattern is typically seen in patients with well-controlled blood pressure and blood sugar on appropriate medications. It does not necessarily indicate treatment failure — some degree of decline over decades is expected even with optimal management — but it warrants continued close monitoring to ensure the decline does not accelerate.

What rapid progression looks like. A decline in eGFR of more than 5 mL/min per year — or any doubling of serum creatinine over a 12-month period — is classified as rapid CKD progression and should prompt immediate re-evaluation. The causes of rapid progression include: uncontrolled blood pressure, inadequate renin-angiotensin blockade, new or worsening proteinuria, a superimposed acute kidney injury (from illness or medication), or the development of a new kidney disease on top of existing CKD. Rapid progression is also the clearest trigger for nephrology referral in a patient who has been managed in primary care.

When ACR moves to a higher category. A patient whose ACR moves from A1 to A2 — or A2 to A3 — between visits has crossed a KDIGO threshold that changes both the monitoring frequency and the treatment intensity. Moving from A1 to A2 typically triggers initiation of an ACE inhibitor or ARB (if not already prescribed) and more frequent monitoring. Moving from A2 to A3 often triggers a nephrology referral and consideration of whether an SGLT-2 inhibitor or finerenone should be added. The threshold-crossing matters as much as the absolute number.

The role of blood pressure at each visit. Blood pressure is measured at every kidney monitoring appointment not as a formality but because it is directly actionable. For patients with CKD and urine albumin above 30 mg/g, each 10 mmHg reduction in systolic blood pressure below 130 mmHg reduces the rate of eGFR decline substantially — this is one of the most evidence-based interventions available for slowing CKD progression, and it is free in the sense that it requires no new medication, only optimizing the dose of an already-prescribed drug. A blood pressure of 148/92 at a monitoring visit is just as important a finding as a creatinine of 1.8, and deserves the same level of attention and follow-through.

Managing Kidney Function Monitoring During Acute Illness

Scheduled monitoring visits are designed for periods of relative stability. Acute illness changes the picture and often requires unscheduled kidney function testing outside the standard schedule.

Gastrointestinal illness with significant vomiting or diarrhea causes dehydration, which reduces renal blood flow and can precipitate pre-renal AKI — particularly in patients who are already taking ACE inhibitors, ARBs, NSAIDs, or SGLT-2 inhibitors. The standard advice for CKD patients who cannot maintain adequate fluid intake during a GI illness is to temporarily hold ACE inhibitors, ARBs, and diuretics (a practice sometimes called a “sick day medication” protocol or “sick day rules”), stay as hydrated as possible with small frequent sips of fluid, and contact their provider if they have not been able to eat or drink for 24 hours. A creatinine check 2 to 3 days into a significant GI illness is appropriate for patients in G3 or beyond.

Fever and systemic infection also reduce effective renal blood flow through vasodilation and fluid redistribution. Any severe infection — pneumonia, pyelonephritis, cellulitis requiring IV antibiotics — can trigger AKI in a CKD patient. If a CKD patient is hospitalized for any reason, a creatinine and electrolytes should be checked on admission and followed daily during the hospitalization, regardless of the primary reason for admission.

Before elective procedures, particularly those involving general anesthesia or IV contrast dye, CKD patients should have a creatinine and eGFR checked within the preceding 3 months. Anesthesia teams need this information to adjust drug dosing; radiologists need it to determine whether contrast can be safely administered and whether prophylactic hydration is needed. If a procedure has been scheduled more than 3 months since the last kidney function check, it is appropriate to request a new test before the procedure date.

During recovery from hospitalization, if any acute kidney injury occurred — even mild AKI Stage 1 — the creatinine must be rechecked 3 months after discharge. Many patients complete a hospitalization, feel better, and do not have follow-up blood work because they feel well. This gap in post-AKI monitoring is one of the most common missed opportunities to detect new or worsening CKD while treatment options are still most effective.

When to Ask for a Referral to Nephrology

Primary care providers are equipped to manage most CKD patients in G1 through G3a with stable disease. But there are specific circumstances where nephrology input changes the management plan in ways that primary care alone cannot provide:

Unexplained proteinuria: If the ACR is above 300 mg/g and the cause is not clearly diabetic nephropathy in a patient with long-standing diabetes and appropriate progression, a nephrologist should be involved. Causes such as IgA nephropathy, membranous nephropathy, focal segmental glomerulosclerosis, or minimal change disease require antibody testing, a kidney biopsy, and disease-specific treatment that differs from the standard ACE inhibitor plus SGLT-2 inhibitor approach.

Hematuria alongside proteinuria: The combination of microscopic hematuria with significant proteinuria — especially with active urinary sediment (RBC casts) — suggests glomerulonephritis that needs characterization and often biopsy. This is not a scenario for watchful waiting; glomerulonephritis can destroy kidney function over months without treatment.

Young patients with CKD: CKD diagnosed in patients under 40 is unusual and should almost always involve nephrology, because the cause is more likely to be a genetic or immune-mediated condition (ADPKD, Alport, IgA nephropathy, lupus nephritis) rather than the age-related diabetic or hypertensive nephrosclerosis seen in older patients. These conditions often have disease-specific treatments that need specialist input.

Resistant or difficult-to-control blood pressure in the context of CKD: If blood pressure cannot be controlled below 140/90 mmHg despite three or more antihypertensive medications including a diuretic in a CKD patient, nephrology should be involved. Renovascular hypertension from renal artery stenosis, primary hyperaldosteronism, and other secondary causes of hypertension are more prevalent in CKD patients and require specialist evaluation. Additionally, the optimal choice of antihypertensive agents and the management of CKD-associated electrolyte problems with multiple medications is within the nephrology skill set.

Planning for end-stage kidney disease: When eGFR falls below 20, the conversation about renal replacement therapy — hemodialysis, peritoneal dialysis, or preemptive kidney transplant — should begin at least 1 to 2 years before dialysis is expected to be needed. This is because creating an arteriovenous fistula for hemodialysis requires months to mature before it can be used, and getting onto a transplant waiting list involves an evaluation process that takes months. Waiting until dialysis is urgently needed removes the patient’s ability to plan and choose their modality thoughtfully, and dramatically worsens outcomes.

Practical Tips for Staying on Schedule

The biggest barrier to consistent kidney monitoring is not the test itself — it is remembering to schedule it, getting the right tests ordered, and following up on results. The following practical strategies help patients stay on track:

Tie testing to an annual event. For patients who require annual monitoring, linking the test to a predictable anchor — a birthday, an annual physical, a seasonal flu vaccine appointment — makes it easier to remember year after year without relying on a reminder from the clinic. Many clinic systems do not proactively reach out to patients for routine monitoring; the patient often has to initiate the appointment.

Keep a personal record of your results. Ask for a printed or electronic copy of each kidney function test result. Over time, a simple table with the date, creatinine, eGFR, and ACR value gives both you and your provider a clear visual of the trajectory. If you change primary care providers, this personal record ensures continuity of monitoring without having to reconstruct your history from scratch.

Ask specifically about ACR at each visit. Many kidney function “panels” ordered in primary care include only the blood tests — creatinine, BUN, and electrolytes — without the urine ACR. Patients with diabetes or hypertension should specifically ask at each annual visit whether a urine albumin test was ordered. If it was not, ask for it to be added — it requires only a small urine sample and is covered by most insurance plans for these indications.

Set medication reminders for sick-day protocols. Patients on ACE inhibitors, ARBs, or diuretics should have a written sick-day plan from their provider explaining which medications to hold if they develop significant vomiting or diarrhea, and when to seek medical attention. Having this plan ready before illness strikes prevents the common scenario of a dehydrated patient taking their usual kidney medications and precipitating an AKI that could have been avoided.